Deutsche Bank analyst Emmanuel Papadakis upgraded Sanofi (SNY) to Buy from Hold with a price target of EUR 110, up from EUR 90. The firm expects the Phase 3 results for amlitelimab in atopic dermatitis to be positive. With a de-rated multiple, Sanofi shares offer an attractive risk/reward into the readout, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- FDA approves Sanofi’s Wayrilz as BTK inhibitor for immune thrombocytopenia
- Sanofi’s Rilzabrutinib Gains EU Orphan Designation for IgG4-Related Disease
- Novavax 2025-2026 Formula COVID-19 vaccine approved in U.S.
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Prurigo Nodularis Treatment